Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a dismal outcome. To improve understanding of sequential microbiome changes during PDAC development we analyzed mouse models of pancreatic carcinogenesis (KC mice recapitulating pre-invasive PanIN formation, as well as KPC mice recapitulating invasive PDAC) during early tumor development and subsequent tumor progression. Diversity and community composition were analyzed depending on genotype, age, and gender. Both mouse models demonstrated concordant abundance changes of several genera influenced by one or more of the investigated factors. Abundance was significantly impacted by gender, highlighting the need to further elucidate the impact of gender differences. The findings underline the importance of the microbiome in PDAC development and indicate that microbiological screening of patients at risk and targeting the microbiome in PDAC development may be feasible in future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225934 | PMC |
| http://dx.doi.org/10.1016/j.isci.2023.106841 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GALNT4-induced O-GalNAc glycosylation of MUC1 accelerates the invasive phenotype of PDAC.
Pancreatology
August 2025
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, remains a therapeutic challenge. While GALNT4 (a member of the N-acetylgalactosaminyltransferases family) shows significant upregulation in PDAC cells, its precise oncogenic mechanisms remain poorly understood.
Methods: Bioinformatics analysis was performed to examine the expression of GALNT4 and MUC1 in pancreatic adenocarcinoma (PAAD) and to predict the glycosylation sites of MUC1.
Nuclear cGAS mediated Replication Stress and Mitotic Catastrophe can Overcome Gemcitabine Resistance.
Cancer Lett
September 2025
Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA; Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, OR, USA.
Gemcitabine, a ribonucleotide reductase (RNR) inhibitor, is active in pancreatic ductal carcinoma (PDAC) patients, but unfortunately has a limited impact on long term outcomes. Gemcitabine induces nucleotide deficiency, DNA damage including single stranded DNA (ssDNA) and replication stress (RS). DNA damage can activate cyclic GMP-AMP synthase (cGAS), leading to genome instability, micronucleus generation, and immune activation.
View Article and Find Full Text PDFRobotic superior mesenteric and portal vein resections in major liver, biliary, and pancreatic surgery.
Updates Surg
September 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena "Policlinico", University of Modena and Reggio Emilia, 41124, Modena, Italy.
The robotic approach to liver and pancreatic surgery is expanding worldwide. However, limited data are available on vascular management in these complex procedures. The unique characteristics of the robotic platform may enhance the feasibility of minimally invasive vascular resection and reconstruction.
View Article and Find Full Text PDFDiagnosis methods for pancreatic cancer with the technique of deep learning: a review and a meta-analysis.
Front Oncol
August 2025
Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Early diagnosis can significantly improve survival rate of Pancreatic ductal adenocarcinoma (PDAC), but due to the insidious and non-specific early symptoms, most patients are not suitable for surgery when diagnosed. Traditional imaging techniques and an increasing number of non-imaging diagnostic methods have been used for the early diagnosis of pancreatic cancer (PC) through deep learning (DL).
Objective: This review summarizes diagnosis methods for pancreatic cancer with the technique of deep learning and looks forward to the future development directions of deep learning for early diagnosis of pancreatic cancer.
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.
Sci Transl Med
September 2025
University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class allele-agnostic mutant-KRAS inhibitor (panKRASi), in pancreatic ductal adenocarcinoma (PDAC).
View Article and Find Full Text PDF